UK biotech rock­ets up on Covid-19 'break­through' for in­haled in­ter­fer­on be­ta — can its small study live up to the boast?

In­ter­fer­on be­ta, a cy­tokine ap­proved and wide­ly used in in­jectable forms, sur­faced very ear­ly on as a po­ten­tial treat­ment for Covid-19. A British biotech now says its in­haled for­mu­la­tion of the drug helped hos­pi­tal­ized pa­tients re­cov­er — and low­ered their risk of do­ing worse.

It’s a small study in­volv­ing on­ly 101 pa­tients and missed some end­points, but Synair­gen said the re­sults could sig­nal a “ma­jor break­through.” If true, that would al­so mark se­ri­ous val­i­da­tion for a drug that As­traZeneca once li­censed but even­tu­al­ly aban­doned as an asth­ma ther­a­py.

First, the pos­i­tives:

  • Pa­tients in the SNG001 arm saw their risk of re­quir­ing ven­ti­la­tion or dy­ing re­duced by 79% com­pared to those who re­ceived place­bo, with a mar­gin­al­ly pos­i­tive p-val­ue of 0.046.
  • They were al­so “more than twice as like­ly to re­cov­er” — to the point where they can go about their dai­ly lives de­spite the in­fec­tion — al­though the dif­fer­ence here wasn’t spelled out (p=0.043).
Stephen Hol­gate

Al­though the com­pa­ny didn’t use the ex­act word­ing, these out­comes ap­pear to align with the pri­ma­ry end­point list­ed on a tri­al post­ing, which mea­sures clin­i­cal im­prove­ment dur­ing the 16-day dos­ing pe­ri­od on an 8-point scale. No fur­ther de­tails on how pa­tients im­proved or wors­ened along that scale were pro­vid­ed.

Shares shot up 173.97% up­on the news, reach­ing 100 GBX on the Lon­don Stock Ex­change.

One oth­er sec­ondary end­point stood out, while oth­ers fell short.

Breath­less­ness, a se­vere symp­tom de­signed to be as­sessed along­side cough and spu­tum, was “marked­ly re­duced” for pa­tients who got the drug (p=0.007). The num­bers for cough and spu­tum weren’t avail­able.

More­over, Synair­gen not­ed, three par­tic­i­pants died af­ter be­ing ran­dom­ized to place­bo, com­pared to ze­ro deaths in the SNG001 group — not that they can draw any con­clu­sion from it.

SNG001 works by send­ing high lo­cal con­cen­tra­tions of in­ter­fer­on be­ta, a “nat­u­ral­ly oc­cur­ring an­tivi­ral pro­tein,” to re­store the lung’s de­fense against the virus, ac­cord­ing to Stephen Hol­gate, a Uni­ver­si­ty of Southamp­ton pro­fes­sor who co-found­ed Synair­gen.

Richard Mars­den

But the tri­al, which was con­duct­ed across 9 sites in the UK, found that pa­tients who al­ready re­quired oxy­gen at ad­mis­sion didn’t seem to ben­e­fit as much. The “nu­mer­i­cal ad­van­tage” in the like­li­hood of hos­pi­tal dis­charge didn’t trans­late to a sta­tis­ti­cal­ly sig­nif­i­cant gain, with me­di­an time to dis­charge in the SNG001 group at 6 days and the place­bo group, 9 days (p=0.096).

Synair­gen al­so want­ed to high­light that pa­tients ap­peared to be more like­ly to have re­cov­ered by the end of treat­ment if they were on the drug, though it was again not sta­tis­ti­cal­ly sig­nif­i­cant.

What does this all mean? The com­pa­ny is con­duct­ing fur­ther analy­sis and it has pre­vi­ous­ly said a piv­otal tri­al would be need­ed. Mars­den said they are now work­ing with reg­u­la­tors and oth­er groups to “progress this po­ten­tial COVID-19 treat­ment as rapid­ly as pos­si­ble.”

It’s un­clear how the da­ta and those from a fol­low-up tri­al would be squared against in­ter­fer­on be­ta ad­min­is­tered in more tra­di­tion­al, com­mer­cial­ly avail­able forms. These are be­ing test­ed in com­bi­na­tion with the HIV drug Kale­tra in both the UK’s RE­COV­ERY tri­al and the WHO-led SOL­I­DAR­I­TY study, two of the largest mas­ter pro­to­cols or­ga­nized to weed out a ros­ter of po­ten­tial Covid-19 drugs.

A study out of Is­rael, pub­lished days ago, con­clud­ed that al­though in­ter­fer­on be­ta “did not change time to reach the clin­i­cal re­sponse, adding to the stan­dard of care sig­nif­i­cant­ly in­creased dis­charge rate on day 14 and de­creased 28-day mor­tal­i­ty.”

Be­fore the pan­dem­ic swept it up, Synair­gen had been test­ing SNG001 in pa­tients with chron­ic ob­struc­tive pul­monary dis­ease. Back in 2014 As­traZeneca in-li­censed the drug for asth­ma and kicked off a study, on­ly to halt it ear­ly in 2016 af­ter de­ter­min­ing that an over­all low num­ber of ex­ac­er­ba­tions among the asth­ma pa­tients re­cruit­ed in that cold sea­son would make it dif­fi­cult to see if they could ac­tu­al­ly hit the pri­ma­ry end­point that had been laid out.

“When we’ve col­lect­ed cells from pa­tients with COPD and asth­ma and old­er peo­ple…we find that their lung cells don’t re­spond very well to virus­es,” Mars­den told End­points News in a pre­vi­ous in­ter­view. “We have al­so along the way al­ways rec­og­nized that with an emerg­ing virus, the drug could be used.”

Whether it will be adopt­ed is a whole oth­er ques­tion like­ly won’t take long to an­swer in the fran­tic R&D race for treat­ments.

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

The dynamic in the biotech market has been highly volatile in the last few years, from the high peaks immediately after the COVID vaccine in 2021, to the lowest downturns of the last 20 years in 2022. This uncertainty makes calling the exact timing of the market’s turn something of a fool’s errand, according to Dr. Chen Yu, Founder and Managing Partner of TCG Crossover (TCG X). He speaks with RBC’s Noël Brown, Head of US Biotechnology Investment Banking, about the market’s road ahead and two possible paths for growth.

Casey McPherson shows his daughters Rose (left) and Weston around Everlum Bio, a lab that he co-founded to spark a treatment for Rose and others with ultra-rare conditions. (Ilana Panich-Linsman)

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

Under bright lab lights, Casey McPherson holds his 6-year-old daughter, Rose. His free hand directs Rose’s gaze toward a computer screen with potential clues in treating her one-of-a kind genetic condition.

Gray specks on the screen show her cells that scientists reprogrammed with the goal of zeroing in on a custom medicine. McPherson co-founded the lab, Everlum Bio, to spark a treatment for Rose — and others like her. A regarded singer-songwriter, McPherson never imagined going into drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Dave Marek, Myovant CEO

My­ovant board balks as ma­jor­i­ty own­er Sum­it­o­mo swoops in with a $2.5B deal to buy them out

Three years after Sumitomo scooped up Roivant’s 46% stake in the publicly traded Myovant $MYOV as part of a 5-company, $3 billion deal, they’re coming back for the whole thing.

But these other investors at Myovant want more than what the Japanese pharma company is currently offering to pay at this stage.

Sumitomo is bidding $22.75 a share for the outstanding stock, which now represents 48% of the company after Sumitomo bumped its ownership since the original deal with Roivant. Myovant, however, created a special committee on the board, and they’re shaking their heads over the offer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Vlad Coric, Biohaven CEO

Vlad Coric charts course for new Bio­haven with neu­ro­science push and Big Phar­ma vets on board

What’s Biohaven without its CGRP portfolio? That’s what CEO Vlad Coric is tasked with deciding as he maps out the new Biohaven post-Pfizer takeover.

Pfizer officially scooped up Biohaven’s CGRP assets on Monday, including blockbuster migraine drug Nurtec and the investigational zavegepant, for $11.6 billion. As a result, Coric spun the broader pipeline into an independent company on Tuesday — with the same R&D team behind Nurtec but about 1,000 fewer staffers and a renewed focus on neuroscience and rare disease.

In AstraZeneca's latest campaign, wild eosinophils called Phils personify the acting up often seen in uncontrolled asthma

As­traZeneca de­buts an­noy­ing pur­ple ‘Phil’ crea­tures, per­son­i­fied asth­ma eosinophils ‘be­hav­ing bad­ly’

There are some odd-looking purple creatures lurking around the halls of AstraZenca lately. The “Phil” character cutouts are purple, personified eosinophils with big buggy eyes and wide mouths, and they’re a part of AZ’s newest awareness effort to help people understand eosinophilic asthma.

The “Asthma Behaving Badly” characters aren’t only on the walls at AZ to show the new campaign to employees, however. The “Phils” are also showing up online on the campaign website, and in digital and social ads and posts on Facebook and Instagram.

Christophe Bourdon, Leo Pharma CEO

Leo Phar­ma looks 'be­yond the skin' in atopic der­mati­tis aware­ness cam­paign

As Leo Pharma aims to take on heavyweight champ Dupixent in atopic dermatitis, the company is launching “AD Days Around the World,” an awareness campaign documenting real patient stories across Europe.

The project, unveiled on Monday, spotlights four patients: Marjolaine, Laura, Julia and África from France, Italy, Germany and Spain, respectively, in short video clips on the challenges of living with AD, the most common form of eczema.

Marc Dunoyer, Alexion CEO (AstraZeneca via YouTube)

Up­dat­ed: As­traZeneca nabs a small rare dis­ease gene ther­a­py play­er for 667% pre­mi­um

AstraZeneca is kicking off the fourth quarter with a little M&A Monday for a gene editing player recently overcoming a second clinical hold to its only program in human studies.

The Big Pharma and its subsidiary Alexion are buying out little LogicBio for $2.07 per share. That’s good for a massive 667% premium over its Friday closing price, when it headed into the weekend at 27 cents and just weeks after Nasdaq said LogicBio would have to delist, which has been put on hold as the biotech requests a hearing. It’s one of two biotech deals to commence October, alongside the news of Incyte buying a vitiligo-focused biotech.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Ying Huang, Legend CEO

Lentivi­ral vec­tor ramp-up: J&J and Leg­end to in­vest $500M in New Jer­sey man­u­fac­tur­ing to sup­port Carvyk­ti

In response to a question on manufacturing scale at Legend Biotech’s R&D day yesterday, the company’s top exec said its partnership with Johnson & Johnson will be doubling its investment in its New Jersey manufacturing center and will be investing a total of $500 million.

With an eye on their BCMA-directed CAR-T therapy Carvykti (cilta-cel), approved in February as a fifth-line treatment for multiple myeloma, Legend CEO Ying Huang said that the ramp-up in production and the decision to manufacture its own lentiviral vectors — currently in shortage worldwide — means they won’t have to deal with that shortage.

Kite Phar­ma gets FDA to sign off on new Cal­i­for­nia-based vec­tor man­u­fac­tur­ing fa­cil­i­ty

Kite Pharma just got FDA approval to kick off operations at a new manufacturing campus.

The cancer-focused, CAR-T cell therapy player made the announcement Monday, saying that the federal regulatory agency gave the green light to Kite’s 100,000 square-foot, retroviral vector manufacturing facility in Oceanside, CA.

Kite’s global head of technical operations Chris McDonald tells Endpoints News that the facility has been in the works for about four years, after Kite teamed up with its parent company Gilead. Gilead acquired Kite Pharma for just shy of $12 billion in 2017.